Insulin Resistance Surge Fueling Growth In The Non-Alcoholic Steatohepatitis Treatment Market: Pivotal Factor Influencing Non-Alcoholic Steatohepatitis Treatment Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Non-Alcoholic Steatohepatitis Treatment Market Size Growth Forecast: What to Expect by 2025?
In the last few years, the market for non-alcoholic steatohepatitis treatment has seen a substantial increase in size. It is expected to increase from $2.6 billion in 2024 to $3.57 billion in 2025, boasting a compound annual growth rate (CAGR) of 37.5%. The notable growth during the past years is due to factors like the increased occurrence of NASH, heightened awareness and diagnosis, changes in lifestyle and the obesity crisis, advancements in clinical research, improvements in healthcare infrastructure and accessibility, regulatory support and progresses in clinical trials.

How Will the Non-Alcoholic Steatohepatitis Treatment Market Size Evolve and Grow by 2029?
Over the coming years, the market size for non-alcoholic steatohepatitis treatment is anticipated to experience a rapid expansion. The projected growth is to " $13.57 billion in 2029, with an impressive compound annual growth rate (CAGR) of 39.6%. Factors contributing to this predicted growth during the forecast period encompass progress in drug development, heightened awareness of the disease, an increase in prevalence and risk factors, and a switch towards bespoke medicine. The forecast period will also witness major trends such as a more patient-focused approach, technological developments, targeted treatments, changes in the regulatory environment, and advancements in research.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Drivers Are Propelling the Growth of Non-Alcoholic Steatohepatitis Treatment Market Forward?
The non-alcoholic steatohepatitis treatment market is experiencing growth spurred by an increasing rate of insulin resistance. Insulin resistance is a condition where cells in muscles, fat, and the liver respond inadequately to insulin, leading to difficulty in absorbing glucose from the blood and essentially causing high blood sugar levels. This condition is generally linked to poor lifestyle choices, excessive sugar intake, and genetic factors. The number of insulin resistance cases has surged due to rising incidences of diabetes and other problems associated with the liver, which are managed using non-alcoholic steatohepatitis treatment. For example, a report by the International Diabetes Federation released in January 2022 highlights that diabetes currently affects 537 million individuals aged 20-79 years, accounting for one in every ten persons. This number is projected to rise to 643 million by 2030 and 783 million by 2045. Additionally, in January 2024, the American Cancer Society has forecasted a rise in the number of new liver cancer cases to 41,630 in 2024, an increase from 41,210 in 2023. Consequently, the elevated occurrence of insulin resistance driven by multiple liver diseases and diabetes is fueling the growth of the non-alcoholic steatohepatitis treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Non-Alcoholic Steatohepatitis Treatment Market?
One of the key trends in the non-alcoholic steatohepatitis (NASH) treatment market is the advancement of NASH drugs. Numerous corporations are focusing their efforts on creating novel drugs for liver disease treatments that come with fewer side effects. For instance, Pfizer Inc., a US-based pharmaceutical and biotech firm, received a fast-track designation grant from the U.S. Food and Drug Administration (FDA) in May 2022. This grant was intended to expedite the development of Pfizer's non-alcoholic steatohepatitis (NASH) drugs, specifically ervogastat and clesacostat. The Fast Track process is aimed at advancing Pfizer's experimental combination therapy for treating non-alcoholic steatohepatitis (NASH) with liver fibrosis. This involves ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

What Are the Key Segments in the Non-Alcoholic Steatohepatitis Treatment Market?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented -

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Who Are the Key Players Shaping the Non-Alcoholic Steatohepatitis Treatment Market's Competitive Landscape?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

What Geographic Markets Are Powering Growth in the Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.